India’s Dr Reddy's Laboratories (NYSE: RDY) has reported third-quarter profits of 5.8 billion rupees ($85 million).
The figure shows a 1% rise on the previous three months but falls short of analyst expectations of around 6.6 billion rupees.
Sales in the three-month period lifted 3% to 39.7 billion rupees.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze